دورية أكاديمية
An updated analysis on myocarditis and pericarditis cases reported following mRNA SARS-CoV-2 vaccination in Singapore.
| العنوان: | An updated analysis on myocarditis and pericarditis cases reported following mRNA SARS-CoV-2 vaccination in Singapore. |
|---|---|
| المؤلفون: | Tham MY; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Chan CL; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Toh D; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Poh J; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Lim A; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Soh S; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Peck LF; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Foo B; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Ng A; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Ng P; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Ang PS; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Dorajoo S; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Teo D; Vigilance and Compliance Branch, Health Sciences Authority, Singapore., Lim TW; Department of Cardiology, National University Heart Centre, Singapore., Lim YT; Mount Elizabeth Hospital Singapore, Singapore., Choo J; Cardiology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore., Ding ZP; Department of Cardiology, National Heart Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore., Yeo KK; Department of Cardiology, National Heart Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore., Yap J; Department of Cardiology, National Heart Centre Singapore, Singapore.; Duke-NUS Medical School, Singapore., Tan HX; Vigilance and Compliance Branch, Health Sciences Authority, Singapore. |
| المصدر: | Singapore medical journal [Singapore Med J] 2024 Feb 16. Date of Electronic Publication: 2024 Feb 16. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer - Medknow Country of Publication: India NLM ID: 0404516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2737-5935 (Electronic) Linking ISSN: 00375675 NLM ISO Abbreviation: Singapore Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: July 2022- : [Mumbai] : Wolters Kluwer - Medknow Original Publication: Singapore, Singapore Medical Assn. |
| مستخلص: | Introduction: Messenger ribonucleic acid (mRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been associated with myocarditis/pericarditis, especially in young males. We evaluated the risk of myocarditis/pericarditis following mRNA vaccines by brand, age, sex and dose number in Singapore. Methods: Adverse event reports of myocarditis/pericarditis following mRNA vaccines received by the Health Sciences Authority from 30 December 2020 to 25 July 2022 were included, with a data lock on 30 September 2022. Case adjudication was done by an independent panel of cardiologists using the US Centers for Disease Control and Prevention case definition. Reporting rates were compared with expected rates using historical data from 2018 to 2020. Results: Of the 152 adjudicated cases, males comprised 75.0%. The median age was 30 years. Most cases occurred after Dose 2 (49.3%). The median time to onset was 2 days. Reporting rates were highest in males aged 12-17 years for both primary series (11.5 [95% confidence interval [CI] 6.7-18.4] per 100,000 doses, post-Dose 2) and following booster doses (7.1 [95% CI 3.0-13.9] per 100,000 doses). In children aged 5-11 years, myocarditis remained very rare (0.2 per 100,000 doses). The reporting rates for Booster 1 were generally similar or lower than those for Dose 2. Conclusions: The risk of myocarditis/pericarditis with mRNA vaccines was highest in adolescent males following Dose 2, and this was higher than historically observed background rates. Most cases were clinically mild. The risk of myocarditis should be weighed against the benefits of receiving an mRNA vaccine, keeping in mind that SARS-CoV-2 infections carry substantial risks of myocarditis/pericarditis, as well as the evolving landscape of the disease. (Copyright © 2024 Copyright: © 2024 Singapore Medical Journal.) |
| References: | Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003;289:3283–9. Koh SWC, Loh V, Liow Y, Leong CK, Young D. COVID-19 vaccination strategy in Singapore: Perspectives and lessons from primary care. Singapore Med J 2023 doi: 10.4103/singaporemedj.SMJ-2021-405. (PMID: 10.4103/singaporemedj.SMJ-2021-405) Ministry of Health Singapore. Expert Committee On COVID-19 Vaccination's Assessment on Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination. Available from: https://www.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination's-assessment-on-myocarditis-and-pericarditis-following-mrna-covid-19-vaccination. [Last accessed on 2022 Oct 03]. Ministry of Health, Singapore. Expert Committee On COVID-19 Vaccination. Statement on Skin Reactions after Vaccination and Refraining from Strenuous Physical Activity after Vaccination. Available from: https://www.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination-statement-on-skin-reactions-after-vaccination-and-refraining-from-strenuous-physical-activity-after-vaccination. [Last accessed on 2022 Oct 03]. Ministry of Health, Singapore. Expert Committee On COVID-19 Vaccination: Updates of Assessment on Myocarditis and Pericarditis Following Vaccination with mRNA COVID-19 Vaccines. Available from: https://www.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination-updates-of-assessment-on-myocarditis-and-pericarditis-following-vaccination-with-mrna-covid-19-vaccines. [Last accessed on 2022 Oct 03]. Yap J, Tham MY, Poh J, Toh D, Chan CL, Lim TW, et al. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap 2022;51:96–100. Tan CC, Lam CSP, Matchar DB, Zee YK, Wong JEL. Singapore's health-care system: Key features, challenges, and shifts. Lancet 2021;398:1091–104. Leung YY, Ang LW, Allen JC Jr, Noviani M, Wang R, Yuan JM, et al. Response to Letters to the Editors: 1. More details on the database used by the study should be provided. 2. Mediclaim Hospital Discharge System and income levels of cohort. Osteoarthritis Cartilage 2015;23:499–500. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977–82. Lin W, Yip ACL, Evangelista LKM, Wong RCC, Tan HC, Lim TW, et al. Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech). Pacing Clin Electrophysiol 2022;45:1097–100. Ministry of Health, Singapore. Positive Progress for 16-Year-Old Who had an Out-Of-Hospital Cardiac Arrest after Covid-19 Vaccination. Available from: https://www.moh.gov.sg/news-highlights/details/positive-progress-for-16-year-old-who-had-an-out-of-hospital-cardiac-arrest-after-covid-19-vaccination. [Last accessed on 2022 Oct 03]. Shen X, Koh MSH, Lim BY, Demo-Os M, Chien JMF, Santosa A, et al. Acute pericarditis and cardiac tamponade after Covid-19 vaccination. Singapore Med J 2021. doi: 10.11622/smedj.2021195. (PMID: 10.11622/smedj.2021195) Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet 2022;399:1618–24. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risk of myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex. Circulation 2022;146:743–54. Fishman B, Goitein O, Berkovitch A, Rahav G, Matetzky S. First report of myocarditis in two patients with COVID-19 Omicron variant: Case report. Eur Heart J Case Rep 2022;6:ytac407. Oster ME, Shay DK, Shimabukuro TT. Myocarditis cases after mRNA-based COVID-19 vaccination in the US-reply. JAMA 2022;327:2020–21. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open 2022;5:e2218505. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med 2021;385:2140–9. Cheng DR, Clothier HJ, Morgan HJ, Roney E, Shenton P, Cox N, et al. Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12-17-year olds in Victoria, Australia. BMJ Paediatr Open 2022;6:e001472. doi: 10.1136/bmjpo-2022-001472. (PMID: 10.1136/bmjpo-2022-001472) Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 vaccination and myocarditis in a nordic cohort study of 23 million residents. JAMA Cardiol 2022;7:600–12. Kytö V, Sipilä J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart 2013;99:1681–4. Mevorach D, Anis E, Cedar N, Hasin T, Bromberg M, Goldberg L, et al. Myocarditis after BNT162b2 COVID-19 third booster vaccine in Israel. Circulation 2022;146:802–4. Le Vu S, Bertrand M, Jabagi M-J, Botton J, Weill A, Dray-Spira R, et al. Risk of myocarditis after Covid-19 mRNA vaccination: Impact of booster dose and dosing interval. medRxiv 2022. doi: 2022.07.31.22278064. Shimabukuro T. COVID-19 vaccine safety update: Primary series in young children and booster doses in older children and adults. Advisory Committee on Immunization Practices, September 1, 2022 Meeting. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/05-covid-shimabukuro-508.pdf. [Last accessed on 2022 Oct 03]. Hause AM, Baggs J, Marquez P, Myers TR, Su JR, Blanc PG, et al. Safety monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71:249–54. Shimabukuro T. Update on myocarditis following mRNA COVID-19 vaccination. Vaccines and Related Biological Products Advisory Committee Meeting on June 14 2022. Available from: https://www.fda.gov/media/159228/download. [Last accessed on 2022 Oct 03]. Wong HL. Safety Surveillance of COVID-19 Vaccines in Children and Adolescents-Vaccines and Related Biological Products Advisory Committee Meeting (14 June 2022). Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcement#event-materials. [Last accessed on 2022 Oct 03]. Klein N Myocarditis analyses in the Vaccine Safety Datalink: Rapid cycle analyses and “head-to-head”product comparisons. Advisory Committee on Immunization Practices, February 4, 2022 Meeting. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-04/10-COVID-Klein-508.pdf. [Last accessed on 2022 Oct 03]. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: A cohort study in claims databases. Lancet 2022;399:2191–9. Friman G, Ilbäck NG. Acute infection: Metabolic responses, effects on performance, interaction with exercise, and myocarditis. Int J Sports Med 1998;19 Suppl 3:S172–82. |
| تواريخ الأحداث: | Date Created: 20240216 Latest Revision: 20240216 |
| رمز التحديث: | 20240217 |
| DOI: | 10.4103/singaporemedj.SMJ-2023-089 |
| PMID: | 38363732 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!